Exosomes for skin and hair: what is established and what is marketing
Exosomes are a biological signal, not a filler — and the distance between the laboratory rationale and the published human evidence is the whole story. This page separates what the clinical studies support from what the word is being asked to sell, and states which delivery route is and is not permitted in Brazil.
Agendar ConsultaWhat an exosome is, and what the word is being asked to carry
An exosome is a small extracellular vesicle — 30 to 150 nanometres across — that one cell releases to carry proteins, lipids and nucleic acids to another. In aesthetic medicine it is used as a biological signal, not as a material that occupies space, and the distance between that laboratory rationale and the published human evidence is the whole subject of this page.
That size range and that cargo come from a 2025 review in the Journal of Drugs and Dermatology, which surveyed 56 references published between 2014 and 2024. Its account of the proposed mechanism is specific: in skin, extracellular matrix production and inhibition of matrix metalloproteinases — the enzymes that break that matrix down — and in the scalp, follicle cell activity and modulation of inflammation.
The second thing to understand is that “exosome” names a vehicle, not a fixed formula. A scoping review published in the same journal in 2026 found that the sources used in human studies were predominantly mesenchymal stem cell-derived. A separate systematic review published in Dermatology Practical & Conceptual in 2026 describes products derived from adipose stem cells, platelets, plants and milk. Two vials sold under the same word can therefore hold materials of different origin, different cargo and different manufacturing — which is precisely the problem the 2025 review names when it lists inconsistent isolation methods and source variability among the category’s unresolved challenges.
None of this makes the category empty: it is a biological signal with a genuine rationale and an unfinished file, sold at scale while that file is still being written.
Pre-clinical signal and clinical signal are not the same thing
The gap that matters most here is not between enthusiasts and sceptics. It is between what has been shown in laboratory models and what has been shown in people, and almost every overstatement in this category collapses the two.
The 2026 scoping review states the position in its own framing: in pre-clinical studies exosomes activate dermal repair mechanisms and may show regenerative potential for skin rejuvenation, pigmentation, scarring, hair loss and inflammatory dermatoses — while the clinical landscape and its safety remain undefined, despite commercial availability. The order of that sentence is the point. The products reached the market before the human evidence did.
The hair literature has the same shape. A 2025 review of clinical studies in Dermatologic Surgery summarises the pre-clinical rationale as exosomes fuelling hair growth by stimulating dermal papilla cells, activating hair follicle stem cells and promoting angiogenesis — and then states, in the same abstract, that very limited data are available on the safety and efficacy of exosome use in human subjects.
A mechanism demonstrated in cell culture is a reason to run a trial, not the result of one. A clinic that explains why exosomes work by describing what happens to fibroblasts or dermal papilla cells in a dish is quoting the reason the research began rather than its conclusion — and the patient is being asked to pay for the conclusion.
Topical and device-assisted delivery: the better-documented end
Where the human evidence is least thin, the preparation is applied to the surface — onto intact skin, or immediately after a device has opened transient channels through it.
The clearest single-product result comes from a 2022 study in Aesthetic Surgery Journal of a topical serum derived from human platelet extract, an allogeneic exosome product made from leukocyte-reduced apheresed platelets. Over six weeks, VISIA-CR imaging showed a statistically significant mean improvement of 224.2 points in an overall skin health score against baseline, with significant reductions in redness, wrinkles and melanin. The design caveat belongs in the same breath as the result: prospective, single-arm, non-randomised and six weeks long, run alongside a standardised skin care regimen, so it has no comparator against which the serum’s contribution can be separated.
Randomised evidence is scarce — the 2026 systematic review in Dermatology Practical & Conceptual counted one randomised trial among its 21 studies — and the trial described here tests exosomes as an adjunct to a device. In a randomised controlled study published in Life in 2026, 75 patients with postoperative facial scars received fractional non-ablative Nd:YAG laser alone or the same laser with either a human-derived or a plant-derived exosome skin booster, over five sessions at two-week intervals, assessed with the modified Vancouver Scar Scale, the Patient and Observer Scar Assessment Scale and objective imaging. Compared with laser alone, the added booster was associated with greater short-term improvement in scar appearance and grayscale intensity, with between-group differences meeting the trial’s own significance threshold on the imaging endpoint and the observer-rated scales, though not the patient-rated one. The caveats come from its own authors and belong in the same breath: an exploratory, hypothesis-generating trial, with no power calculation and no adjustment for multiple comparisons — so its p-values are to be read descriptively — no design able to separate the exosomes from the other constituents of the complete commercial formulations tested, and findings that, they write, should not be viewed as evidence of definite efficacy or superiority. Pigmentation, erythema, pore size and fine wrinkle measures also improved in the exosome-treated groups, and no serious adverse events were reported.
One result from that trial deserves attention: clinical responses were comparable between the human-derived and the plant-derived formulations. A category whose pricing frequently rests on the provenance of its source produced similar short-term outcomes from two very different sources — though its authors caution that the trial may be underpowered to detect small differences between the two exosome groups, making that similarity an absence of evidence rather than proof of equivalence.
The wider reviews are equally hedged, and they do not count the same thing. The 2026 systematic review screened 1,032 papers and retained 21 — a mixed set its own authors describe as preclinical in vitro and animal models alongside clinical trials and retrospective evaluations. Its reported gains in elasticity, wrinkle depth, hydration and pigmentation, and its molecular evidence of collagen and elastin synthesis and suppression of matrix metalloproteinases, therefore come from that mixture: those 21 are not 21 studies in people. The 2026 scoping review counts only people — 17 studies in human participants — and there 76% recorded improvement in wrinkles, pigmentation, elasticity, hydration or scars, while its own authors list small sample sizes, short follow-up, non-randomised single-arm designs and potential conflicts of interest as the limits on reading that figure.
Injectable claims, and why the regulatory picture differs by country
Injection is where the claims get loudest, the safety signal sharper, and the law stops being the same in two places at once.
On approval, the 2025 review in the Journal of Drugs and Dermatology is unambiguous: there are currently no US Food and Drug Administration approved exosomes. That is a statement about the position at the time of that 2025 review, which this page does not extend to a later date or to another country’s authority — the same review describes the regulatory landscape as evolving. At that point, a clinic describing an exosome product as FDA-approved was describing something the published literature did not record.
In Brazil the relevant fact is narrower and more concrete: the injectable use of exosomes is not permitted by Anvisa. That is not a matter of clinical preference or of a physician’s appetite for novelty, and it holds regardless of what the international evidence eventually shows.
Safety is the second reason the question is not merely administrative. The 2026 scoping review reports that adverse events across its 17 human studies were uncommon — but that those recorded included granulomas, necrosis and allergic reactions after injection. The route by which the material enters the tissue is part of its risk profile, not a detail of technique.
| Delivery route | What the published clinical literature shows | What changes in regulatory terms |
|---|---|---|
| Topical, on intact skin | One of the four routes across the 17 human studies of the 2026 scoping review. Best measured by the 2022 platelet-extract serum study: significant against baseline, but single-arm and without a comparator. | No drug approval underlies it — the 2025 review records no FDA-approved exosomes as of that review. |
| Topical after microneedling | Listed among the delivery routes of the scoping review’s human studies; transient microchannels carry the material past the surface. | A registered device does not confer approval on the material passed through it. |
| Topical after fractional laser | The laser route listed among the scoping review’s human studies is fractional CO2; the randomised trial above used non-ablative 1064 nm Nd:YAG. That trial — one of the few randomised designs in this literature — found greater short-term scar improvement than laser alone in 75 patients over five sessions, on imaging and observer-rated scales, in an exploratory design with no power calculation and p-values its authors call descriptive. No serious adverse events. | Same principle: the laser is regulated as a device, and the booster’s status is unchanged by being delivered after it. |
| Injection into dermis or scalp | Used in part of the scoping review’s studies, and the route to which its reported granulomas, necrosis and allergic reactions were attributed. | Not permitted in Brazil by Anvisa — the line between what is discussed internationally and what the rule allows locally. |
The practical consequence for anyone comparing clinics across countries is that the same word can describe legally and materially different things, and a clinic that does not volunteer its route has left out the variable that decides both.
Hair: what the signal looks like today
Hair is the indication with the widest gap between the volume of advertising and the volume of published human data.
The 2025 review of clinical studies in Dermatologic Surgery searched PubMed, EMBASE and Cochrane and included 48 studies across exosome use in human subjects — 25 clinical trials, 14 case reports, 4 case series, 1 retrospective review and 4 conference abstracts. Of those, nine clinical studies were relevant to alopecia, and 125 patients in total had received an exosome treatment for hair loss. That is the size of the human file for this indication: not thousands of patients, not dozens of trials.
Within those nine studies, side effects were rare. One further number from the same review has to be reported with its scope attached, because it is routinely misquoted in both directions: in the broader field of dermatology — not among those 125 patients treated for hair loss — at least 10 serious adverse events have been reported. Those two findings describe different populations, and neither one cancels the other.
What that review asks for is the honest close of this section: larger, well-designed clinical trials with extended follow-up, together with consistent manufacturing standards and regulatory oversight. That places exosomes for hair as a reasonable adjunct still under investigation — alongside, and not instead of, the treatments with an established evidence base for androgenetic alopecia.
How to read a clinic’s exosome claim
Most of the confusion in this category is resolvable with four questions, none of which requires the patient to read a paper.
- What is the source, and is it disclosed? Mesenchymal stem cell-derived products predominated among the human studies, while platelet-, plant-, adipose- and milk-derived products also exist. A clinic that cannot name the origin of what it is applying cannot tell you which part of the literature applies.
- By which route is it delivered? Topical, microneedling-assisted, laser-assisted and injected are not interchangeable. They differ in the evidence that supports them and, in Brazil, in whether they are permitted.
- Is the claim about a mechanism or about a result in people? Wnt signalling, fibroblast behaviour and matrix metalloproteinase suppression are mechanisms. Wrinkle depth, scar scales and hair counts measured in patients are results. A page offering only the first is offering the reason the research started.
- Is it being offered instead of something with a longer file? This is the question that costs the most: for a patient whose dominant complaint is descended tissue or lost volume, buying a regenerative signal first postpones the treatment that would have worked.
Two further checks are worth the minute they take. Ask what would count as a result and when it will be assessed — the published protocols measure with standardised imaging at defined weeks. And confirm that the physician’s registration is active, which in Brazil is a public check at cfm.org.br. A treatment whose reviews end by calling for larger trials should be carried out by someone willing to tell you that.
What the protocol does, and what it does not treat
In this practice, exosomes are used within a structured protocol named Exocube, and the delivery route is decided individually at the clinical assessment rather than by a fixed package. Where the route is percutaneous, microneedling or a brief fractional energy pass comes first and the exosome infusion follows immediately, inside the short window before the epidermal barrier begins to restore itself. The protocol runs across three to four sessions spaced three to four weeks apart, with comparative photographic review against baseline at 90 and 180 days, and any maintenance interval defined from that documented response rather than promised in advance.
The regulatory frame belongs in that conversation: as set out above, the injectable use of exosomes is not permitted in Brazil by Anvisa. Which route applies to an individual case is settled at the assessment, against the findings and the rule in force.
The second limit is clinical rather than regulatory, and it decides whether a patient is satisfied. A regenerative protocol addresses tissue quality — luminosity, texture, density and, on the scalp, the environment around the follicle. It does not restore lost volume, reposition descended soft tissue or soften hyperkinetic expression lines. When those are the dominant complaints, the regenerative component belongs alongside structural treatment rather than in place of it, and sequencing the two is the clinical decision. That assessment is made in person with Dr. Thiago Perfeito, CRM-DF 23199, in Brasília.
No commercial relationship with any manufacturer
Dr. Thiago Perfeito’s practice holds no commercial relationship, sponsorship, consultancy or financial arrangement with any manufacturer or distributor of exosome products, of the devices used to deliver them, or of the skincare discussed here. Nothing written above was written to move a particular product.
That declaration has a visible consequence, and it is deliberate: no manufacturer’s exosome product is named anywhere on this page. The 2022 topical study evaluated a specific branded serum, identified here by what it is — a human platelet extract serum — rather than by its brand, because a single-arm six-week study is no basis for sending a reader to buy a named product.
The sources are not uniformly disinterested either, and they say so. The 2026 scoping review lists potential conflicts of interest among the four constraints it places on its own findings. A category can be genuinely promising and simultaneously unfinished; exosomes are currently both. A page that told you otherwise would be selling you something.
Frequently asked questions about exosomes for skin and hair
Do exosomes work for hair loss?
The honest answer is that the human evidence is small and early. A 2025 review of clinical studies in Dermatologic Surgery included 48 studies of exosome use in humans overall, of which nine were relevant to alopecia, covering 125 patients who received an exosome treatment for hair loss; within those studies side effects were rare. The same review notes separately that, in the broader field of dermatology rather than among those 125 patients, at least 10 serious adverse events have been reported. Its own conclusion is that larger, well-designed trials with extended follow-up are needed to prove efficacy, which places exosomes as an adjunct under investigation rather than a replacement for treatments with an established evidence base.
Are exosomes FDA approved?
A 2025 review in the Journal of Drugs and Dermatology states that there are currently no US Food and Drug Administration approved exosomes, and describes the regulatory landscape as evolving. That is the position recorded at the time of that review, and it should not be read as a statement about any later date or about any other country's authority. In Brazil the relevant rule is separate and specific: the injectable use of exosomes is not permitted by Anvisa. Any clinic anywhere describing an exosome product as an approved drug is making a claim the published literature did not support at that point.
What results do exosome treatments actually show for skin?
Consistent but modestly documented improvement in skin quality measures — with the caveat that the two 2026 reviews cited here do not count the same thing. A systematic review in Dermatology Practical & Conceptual retained 21 of 1,032 screened papers, but that set mixes laboratory and animal studies with clinical trials and retrospective evaluations, so its reported gains in elasticity, wrinkle depth, hydration and pigmentation, and its molecular evidence of collagen and elastin synthesis, come from that mixture rather than from studies in people. For results measured in people, the figure to use comes from a 2026 scoping review restricted to 17 studies in human participants, where 76% recorded improvement in wrinkles, pigmentation, elasticity, hydration or scars. That scoping review qualifies its own figure with small samples, short follow-up and largely non-randomised designs, so the direction of the evidence is clearer than its magnitude.
Are exosome injections available in Brazil?
No. The injectable use of exosomes is not permitted in Brazil by Anvisa, regardless of what is published or practised abroad. A patient who has read about injected exosomes in another country has read about a route with a different regulatory status and a different safety profile. Which delivery route applies to an individual case is decided at the clinical assessment, within what is permitted here, and the page on the Exocube protocol describes how that protocol is structured.
Are exosome treatments safe?
Reported adverse events are uncommon, but they are not absent and they are not evenly distributed across delivery routes. A 2026 scoping review of 17 human studies found adverse events uncommon while recording granulomas, necrosis and allergic reactions after injection. In the 2026 randomised study of laser-assisted delivery in 75 patients with postoperative facial scars, no serious adverse events were reported. That scoping review and that randomised study both report short follow-up, so long-term safety is not established by the studies consulted for this page.
How many exosome sessions are needed and how far apart?
No single validated protocol emerges from the studies consulted here, and they differ from one another. The 2026 randomised study of laser-assisted delivery used five sessions at two-week intervals. In this practice the structured protocol runs across three to four sessions spaced three to four weeks apart, with comparative photographic review against baseline at 90 and 180 days, and any maintenance interval defined from that documented response rather than fixed in advance. Because the published follow-up in this category is short, a plan that promises a specific durability is promising something these studies have not measured.
Are plant-derived exosomes as good as human-derived ones?
In a randomised trial that compared them directly they performed comparably. The 2026 study in Life allocated 75 patients with postoperative facial scars to fractional non-ablative Nd:YAG laser alone or combined with a human-derived or a plant-derived exosome booster over five sessions, and reported that clinical responses were comparable between the two formulations. Its authors also note that the trial may be underpowered to detect small differences between those two groups in particular, so that comparability is an absence of a measured difference rather than proof of equivalence. It is a single short-term trial in one indication, so it is not a general ruling on source, but it does mean that a price premium justified purely by the provenance of the source is not supported by that comparison.
References
- Wang OJE, Bajwa BB, Rivers JK. Exosome-Based Therapies in Dermatology: A Scoping Review. J Drugs Dermatol. 2026;25(4):368-376. PMID: 41931695 · doi:10.36849/jdd.9610
- Haykal D, Wyles S, Garibyan L et al. Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges. J Drugs Dermatol. 2025;24(1):12-18. PMID: 39761139 · doi:10.36849/JDD.8872
- Park JY, Park JH. Randomized Clinical Study of Laser-Assisted Delivery of Exosome Boosters for Postoperative Facial Scars and Facial Rejuvenation. Life (Basel). 2026;16(2). PMID: 41752855 · doi:10.3390/life16020217
- Proffer SL, Paradise CR, DeGrazia E et al. Efficacy and Tolerability of Topical Platelet Exosomes for Skin Rejuvenation: Six-Week Results. Aesthet Surg J. 2022;42(10):1185-1193. PMID: 35689936 · doi:10.1093/asj/sjac149
- Queen D, Avram MR. Exosomes for Treating Hair Loss: A Review of Clinical Studies. Dermatol Surg. 2025;51(4):409-415. PMID: 39447204 · doi:10.1097/DSS.0000000000004480
- Alzahrani A, Alghamdi S, Alahmadi M et al. Exosomes in Skin Rejuvenation: Systematic Review of Anti-Aging Effects and Clinical Applications. Dermatol Pract Concept. 2026;16(1). PMID: 41912205 · doi:10.5826/dpc.1601a6462
Reviewed by Dr. Thiago Perfeito — Aesthetic and Regenerative Medicine, CRM-DF 23199. Updated on .
Unsure whether a regenerative protocol is the right tool for your case?
This category treats tissue quality, not lost volume or descended tissue — and telling those two complaints apart is the whole decision. Dr. Thiago Perfeito can assess which applies to you during a consultation in Brasília.